Quantum-Si incorporated (QSI) Stock: Price, Forecast & Analyst Target
Quantum-Si incorporated (QSI) — MoonshotScore 26/100 (Weak band), calculated Oct 6, 2026. Price $1.28 (-17.42%), as of the Oct 5, 2026 trading session; market cap $253M. Expected results Nov 4, 2026.
Listing-status flag — 8-K Item 3.01, filed Jul 24, 2026. Cure deadline stated in filing: Jan 19, 2027.
Educational signal · not a buy or sell recommendation · How to read this
Market value / cash and short-term investments: 2.26× (market value Oct 5, 2026; cash Jun 30, 2026) · expected results Nov 4, 2026
Quantum-Si incorporated · QSI · NASDAQ · Healthcare · Medical - Devices
Research dated 2026-09-13: Quantum-Si sells a semiconductor-derived platform for detecting individual protein molecules, placing the company closer to an emerging protein-sequencing instrument developer than a conventional medical-device manufacturer. Product adoption remains far too small to absorb the research and commercial cost base. Proteus execution now carries the story: its delayed launch must translate into meaningful demand before persistent cash burn narrows the financing cushion.
Price as of Oct 5, 2026
Key Statistics
MoonshotScore v2 · Quantum-Si (QSI)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Strong price action running well ahead of the business — bottom-tier quality underneath; a move to treat with suspicion, not chase. Business Quality: Poor; Financial Safety: Okay; Valuation: Rich; Growth Durability: Fading; Momentum: Rising.
- quarterly revenue $344,000 (Q2 FY2026, quarter ended Jun 2026)
- EPS beat 5 of 8
- Altman Z 7.42 · Piotroski F 2
Holding back: weak fundamentals, a rich price
Helping: positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 22 | Weak | |
| 25 | Weak | |
| 25 | Weak | |
| 25 | Weak | |
| 25 | Weak | |
| 26 | Weak |
The score was 26 in the stored Oct 5, 2026 snapshot and remains 26 in the current publication computed Oct 6, 2026 (0); the largest pillar moves were Momentum -13 and Valuation -2; the pillar moves offset under the sector-relative weighting, so the headline score is unchanged. This current publication is not yet represented in the immutable snapshot archive.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · Educational signal · not a buy or sell recommendation · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $1.28 | |
| Change on the day | -17.42% | |
| 52-week range | $0.69 – $3.10 | |
| Market capitalisation | $253M | |
| Shares traded on the day | 19.1M | |
| Beta (volatility vs the S&P 500) | 3.25 |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · below the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Listing notice
- · Earnings call · Proteus launch → Q2 2027
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
Chronological order, not a duration scale. Periods are stated windows, not exact dates. Management expectations and provider estimates can change.
Read management statementsCouncil Score · weighted blend of 2 available disciplines
Council score for Quantum-Si (QSI): Split View
40/100 · CSome lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
5 lenses, 5 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Oct 5, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
Three of these lenses read this company more favourably than the MoonshotScore does: Dalio-style lens, Griffin-style lens and Englander-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
On Sep 9, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.
Readings on this page are from Oct 6, 2026, except a card that shows its own read date.
Watch the QSI film — every key number, told as a short cinematic story
~2 min · open the film
What is Quantum-Si (QSI), and what does it report?
Short answer · as of
Quantum-Si is developing instruments that apply semiconductor technology to protein sequencing through individual-molecule detection.
Research dated 2026-09-13.
Quantum-Si is developing instruments that apply semiconductor technology to protein sequencing through individual-molecule detection. Reported revenue is predominantly product sales, with services contributing only a small portion, so the income statement mainly reflects early instrument commercialization rather than a scaled service business. Revenue remains tiny beside research spending and operating losses, making reported growth sensitive to modest changes in product shipments.
What do the latest results show for Quantum-Si (QSI)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $344,000.
Research dated 2026-09-13.
The latest period brought a sequential revenue rebound and stronger gross profit, while operating loss widened as research spending increased. Revenue also surpassed the corresponding analyst estimate after a run of misses, but it remained below levels recorded during much of the preceding series. Operating cash outflow improved from the prior period, though the business still consumed far more cash than it generated in sales.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
- Latest quarter · revenue
- $344,000 Jun 30, 2026
- Latest quarter · R&D
- $15.82M Jun 30, 2026
- Latest quarter · SG&A
- $9.98M Jun 30, 2026
- Latest quarter · FMP standardized operating result
- −$25.63M Jun 30, 2026
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Jun 30, 2026 | $344,000 | $15.82M | $9.98M | −$25.63M |
| Mar 31, 2026 | $258,000 | $14.49M | $9.64M | −$24.05M |
| Dec 31, 2025 | $451,000 | $10.95M | $10.27M | −$21.09M |
| Sep 30, 2025 | $552,000 | $13.88M | $10.71M | −$24.40M |
USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $344,000 Aug 13, 2026
- Latest report · revenue estimate
- $302,000 Aug 13, 2026
- Latest report · revenue vs estimate
- Above estimate Aug 13, 2026
- Latest report · EPS vs estimate
- Above estimate Aug 13, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Aug 13, 2026 | $344,000 | $302,000 | −$0.1100 | −$0.1133 |
| May 7, 2026 | $258,000 | $298,667 | −$0.1000 | −$0.1200 |
| Mar 3, 2026 | $451,000 | $761,900 | −$0.0800 | −$0.1400 |
| Nov 5, 2025 | $552,000 | $599,330 | −$0.1700 | −$0.1200 |
Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $344,000 | -$24M | -$0.11 (diluted) |
| Q1 FY2026 | $258,000 | -$22M | -$0.10 (diluted) |
| Q4 FY2025 | $451,000 | -$18M | -$0.08 (diluted) |
| Q3 FY2025 | $552,000 | -$36M | -$0.17 (diluted) |
What are the financial strengths and risks for Quantum-Si (QSI)?
Short answer
Cash and short-term investments were $111.74M at the Jun 30, 2026 balance-sheet date. Operating cash flow was −$18.44M for the quarter ended Jun 30, 2026, meaning operations used cash. These figures do not establish a cash runway.
Research dated 2026-09-13.
Cash and investments substantially exceed debt and liabilities, giving Quantum-Si meaningful room to continue development despite its losses. That protection is eroding: cash and short-term investments have declined materially across the reported window, operating cash flow remains negative, and weak quality screens reflect a business without established earnings support. Management says workforce reductions and expense controls extend funding through the revised Proteus plan, but the delayed launch and a separate Nasdaq listing-status notice make execution and capital preservation inseparable risks.
Data-derived red flags
- Negative return on equity (-47.3%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
How much cash does the business generate or use?
Quarterly operating cash flow shows cash generated or used by operations.
- Latest quarter · operating cash flow
- −$18.44M Jun 30, 2026
- Previous quarter · operating cash flow
- −$25.64M Mar 31, 2026
| Period end | Operating cash flow | Capital expenditure (reported) |
|---|---|---|
| Jun 30, 2026 | −$18.44M | −$80,000 |
| Mar 31, 2026 | −$25.64M | −$280,000 |
| Dec 31, 2025 | −$16.35M | $20,000 |
| Sep 30, 2025 | −$32.02M | −$900,000 |
Operating cash-flow bars share one scale and show magnitude; negative values mean cash used.
USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway.
What should you watch next at Quantum-Si (QSI)?
Short answer · as of
The next earnings report is expected on Nov 4, 2026. The Nasdaq listing-cure deadline stated in the company's filing is Jan 19, 2027.
Research dated 2026-09-13.
Proteus timing is the most consequential operating marker because management moved the planned launch later while tying its funding horizon to the revised schedule. Before launch, watch whether product revenue sustains its recent rebound, gross profit continues to improve, and operating cash outflow falls without another sharp increase in losses. The scheduled earnings release, subsequent periodic filings, and Nasdaq compliance disclosures should clarify whether commercial traction and liquidity remain aligned with management’s plan.
What management is planning
Management expectations, not completed milestones or guarantees. Selected verbatim excerpts; dates follow the transcript provider.
We have updated the Proteus launch timeline from the end of 2026 to the second quarter of 2027.
Jeffrey Hawkins ·
Taking into account the reduction in force and other operating expense management actions, we now believe we have sufficient capital to support the updated Proteus plan, execute the key activities required for launch and fund operations into the fourth quarter of 2028.
Jeffry Keyes ·
How does Quantum-Si compare with its peers?
Short answer
Quantum-Si's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13.
Quantum-Si differs from mature medical-device businesses because its core proposition is semiconductor-enabled protein sequencing, not a broad portfolio of established clinical products. Product sales dominate its limited revenue, while research expense and cash consumption still define the financial profile. Cash and investments represent a large share of market value, so comparison with scaled instrument vendors depends less on current sales multiples and more on whether Proteus can move the company from platform development toward repeatable commercialization.
| Company | Price | Market value | Score |
|---|---|---|---|
| $292.30 Oct 5, 2026 | $44.2B | 94 5-pillar Oct 6, 2026 | |
| $15.69 Oct 5, 2026 | $542M | 92 5-pillar Oct 6, 2026 | |
| $22.49 Oct 5, 2026 | $507M | 91 5-pillar Oct 6, 2026 | |
| $28.08 Oct 5, 2026 | $233M | 88 5-pillar Oct 6, 2026 | |
| $9.17 Oct 5, 2026 | $349M | 88 5-pillar Oct 6, 2026 | |
| $19.73 Oct 5, 2026 | $264M | 78 5-pillar Oct 6, 2026 | |
| $12.23 Oct 5, 2026 | $480M | 77 5-pillar Oct 6, 2026 | |
| $9.37 Oct 5, 2026 | $379M | 40 5-pillar Oct 6, 2026 | |
| $22.89 Oct 5, 2026 | $588M | 38 5-pillar Oct 6, 2026 | |
| $5.97 Oct 2, 2026 | $162M | 36 5-pillar Oct 6, 2026 | |
| $2.60 Oct 5, 2026 | $109M | 33 5-pillar Oct 6, 2026 | |
| $8.68 Oct 5, 2026 | $472M | 32 5-pillar Oct 6, 2026 | |
| Quantum-Si (QSI) — this page | $1.28 | $253M | 26 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $1.90 – $1.90
- Consensus target
- $1.90
- Median target
- $1.90
Consensus record · Captured .
Measured against a quoted price of $1.28 (as of Oct 5, 2026).
Insider activity
Form 4 records via FMP · Of the newest 15 records, those within the last 180 days, newest dated Sep 22, 2026
- Transactions
- 15
- Identified insiders
- 5
- Purchases
- 0
- Sales
- 14
- Other transactions
- 1
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
- Institutional ownership
- 24.3% Period end Jun 30, 2026
- Previous quarter · ownership
- 29.2% Prior to period end Jun 30, 2026
- Reporting holders
- 148 Period end Jun 30, 2026
- Previous quarter · holders
- 164 Prior to period end Jun 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Vanguard Capital Management LLC | 7,578,208 |
| Ark Investment Management LLC | 7,167,738 |
| Blackrock, INC. | 5,225,352 |
| Nikko Asset Management Americas, INC. | 3,885,230 |
| Sumitomo Mitsui Trust Group, INC. | 3,885,230 |
Quarterly filings lag the period end. Holder rows are names in the provider snapshot, not a verified ranking; individual filing dates are not supplied. Related managers may appear separately, so these positions are not summed. Holder snapshot as of Jun 30, 2026.
Quantum-Si Healthcare Stock: Key Questions Answered
Research dated 2026-09-13; the answers below are from that research, and the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
Why does the Proteus delay matter for Quantum-Si?
Proteus is the company’s major planned launch, and its revised timing pushes the commercial proof point further out while losses and cash consumption continue. Management says cost reductions support the updated plan, making spending discipline as important as launch execution.
Are Quantum-Si sales mainly products or services?
Product revenue dominates, while services contribute only a small share. The reported sales base therefore depends primarily on early product commercialization rather than a substantial service stream.
Can Quantum-Si fund the revised Proteus plan?
Management says current capital, workforce reductions, and other expense actions can fund operations through the revised plan. Cash and investments remain substantial relative to debt, but continuing operating outflows mean that claim depends on disciplined spending and launch progress.
What does the Nasdaq listing-status notice mean for QSI?
The notice identifies a failure to satisfy a continued listing rule or standard, adding a compliance risk separate from product development and cash burn. Subsequent company disclosures should be watched for changes in listing status.
What is the QSI stock price today?
The last price recorded on this page for Quantum-Si incorporated (QSI) is $1.28, as of the Oct 5, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the QSI price target?
The analyst consensus price target for Quantum-Si incorporated (QSI) is $1.90 (range $1.90 to $1.90, median $1.90), per FMP data captured Oct 5, 2026. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are shown with each answer. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (89 figures)
The 89 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
OFFICIAL — 7 facts from SEC filings and earnings calls
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
list.rule_notice | Listing-status notice (8-K Item 3.01) | 8-K Item 3.01, filed Jul 24, 2026 | OFFICIAL | SEC EDGAR — Form 8-K, Item 3.01 — Item 3.01 covers both continued-listing notices and voluntary transfers between exchanges; the filing states which applies and any cure terms. | |
list.cure_deadline | Cure deadline stated in the filing | Jan 19, 2027 | OFFICIAL | SEC EDGAR — Form 8-K, Item 3.01 — reviewed filing terms — Initial terms as filed on July 24, 2026. This reviewed supplement did not exhaustively verify later filings or current compliance status. | |
prod.outlook | Management outlook — call excerpts | Jeffrey Hawkins (Aug 12, 2026): We have updated the Proteus launch timeline from the end of 2026 to the second quarter of 2027. Jeffry Keyes (Aug 12, 2026): Taking into account the reduction in force and other operating expense management actions, we now believe we have sufficient capital to support the updated Proteus plan, execute the key activities required for launch and fund operations into the fourth quarter of 2028. | OFFICIAL | Company earnings call, transcript via Financial Modeling Prep (FMP) — Selected verbatim statements from the latest available call, dated by the transcript provider. Management expectations, not completed milestones or guarantees. Relative dates retain the speaker's wording. | |
id.hq | SEC filing business address | Branford, CT | OFFICIAL | SEC EDGAR filer business address — The SEC filer business address. Our market-data provider separately lists "29 Business Park Drive, Branford, CT, 06405, US". The FMP company description names Guilford, Connecticut as the headquarters; this page uses the address in this row. | |
list.reviewed_cure_terms.000181643126000049 | Reviewed initial listing-cure terms | Initial listing-cure terms as filed 2026-07-24 | OFFICIAL | SEC EDGAR — Form 8-K, Item 3.01 — reviewed filing terms — Initial terms as filed on July 24, 2026. This reviewed supplement did not exhaustively verify later filings or current compliance status. | |
list.cure_requirement | Cure requirement in the filing | A closing bid price of at least $1.00 per share for at least 10 consecutive business days; Nasdaq may require a longer period. | OFFICIAL | SEC EDGAR — Form 8-K, Item 3.01 — reviewed filing terms — Initial terms as filed on July 24, 2026. This reviewed supplement did not exhaustively verify later filings or current compliance status. | |
list.if_uncured | Potential consequence if uncured, as filed | If compliance is not regained by the initial deadline, a further 180-calendar-day period is conditional on meeting Nasdaq eligibility requirements and is not guaranteed; otherwise Nasdaq may issue a delisting determination. The notice did not immediately delist the shares. | OFFICIAL | SEC EDGAR — Form 8-K, Item 3.01 — reviewed filing terms — Initial terms as filed on July 24, 2026. This reviewed supplement did not exhaustively verify later filings or current compliance status. |
FMP — 73 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.next | Next earnings date | Nov 4, 2026 | FMP | Financial Modeling Prep (FMP) earnings calendar — The date is our provider's estimate until the company confirms it. | |
px.last | Latest provided price | $1.28 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-05T20:00:01.000Z. | |
px.change | Change on the day | -17.42% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $253M | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-05. FMP quote timestamp: 2026-10-05T20:00:01.000Z. Captured from FMP at 2026-10-06T06:32:34.238Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
px.change_abs | Change on the day, in dollars | −$0.27 | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q2 FY2026 | $344,000 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
px.volume | Shares traded on the day | 19.1M | FMP | Financial Modeling Prep (FMP) · quote | |
px.beta | Beta | 3.25 | FMP | Financial Modeling Prep (FMP) company profile | |
id.ceo | Chief executive | Jeffrey Alan Hawkins | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
id.founder | Founder named in the filing | Jonathan Rothberg — Founder & Executive Director | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
id.employees | Employees | 145 | FMP | Financial Modeling Prep (FMP) employee count, from the company's filing | |
fin.annual | Revenue and net result by fiscal year | 5 fiscal years, FY2021 through FY2025: FY2021 revenue $0.00, net result −$94.99M; FY2022 revenue $0.00, net result −$132.44M; FY2023 revenue $1.08M, net result −$95.96M; FY2024 revenue $3.06M, net result −$101.01M; FY2025 revenue $2.44M, net result −$101.34M | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements | |
fin.rev_mix | Reported revenue segments | Product $2.29M · Service $150,000 | FMP | Financial Modeling Prep (FMP) revenue segmentation, from the company's 10-K | |
fin.gross_margin | Gross margin (trailing twelve months) | 35.0% | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
fin.q_table.depth.2026-06-30.revenue_k | Revenue — period end 2026-06-30 | $344,000 | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.rd_k | R&D — period end 2026-06-30 | $15.82M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.sga_k | SG&A — period end 2026-06-30 | $9.98M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.operating_result_k | FMP standardized operating result — period end 2026-06-30 | −$25.63M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.revenue_k | Revenue — period end 2026-03-31 | $258,000 | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.rd_k | R&D — period end 2026-03-31 | $14.49M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.sga_k | SG&A — period end 2026-03-31 | $9.64M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.operating_result_k | FMP standardized operating result — period end 2026-03-31 | −$24.05M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.revenue_k | Revenue — period end 2025-12-31 | $451,000 | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.rd_k | R&D — period end 2025-12-31 | $10.95M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.sga_k | SG&A — period end 2025-12-31 | $10.27M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.operating_result_k | FMP standardized operating result — period end 2025-12-31 | −$21.09M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.revenue_k | Revenue — period end 2025-09-30 | $552,000 | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.rd_k | R&D — period end 2025-09-30 | $13.88M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.sga_k | SG&A — period end 2025-09-30 | $10.71M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.operating_result_k | FMP standardized operating result — period end 2025-09-30 | −$24.40M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
earn.history.depth.2026-08-13.revenue_actual | Revenue · reported — report date 2026-08-13 | $344,000 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-13.revenue_estimated | Revenue · estimate — report date 2026-08-13 | $302,000 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-13.eps_actual | EPS · reported — report date 2026-08-13 | −$0.1100 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-13.eps_estimated | EPS · estimate — report date 2026-08-13 | −$0.1133 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-07.revenue_actual | Revenue · reported — report date 2026-05-07 | $258,000 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-07.revenue_estimated | Revenue · estimate — report date 2026-05-07 | $298,667 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-07.eps_actual | EPS · reported — report date 2026-05-07 | −$0.1000 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-07.eps_estimated | EPS · estimate — report date 2026-05-07 | −$0.1200 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-03-03.revenue_actual | Revenue · reported — report date 2026-03-03 | $451,000 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-03-03.revenue_estimated | Revenue · estimate — report date 2026-03-03 | $761,900 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-03-03.eps_actual | EPS · reported — report date 2026-03-03 | −$0.0800 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-03-03.eps_estimated | EPS · estimate — report date 2026-03-03 | −$0.1400 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-05.revenue_actual | Revenue · reported — report date 2025-11-05 | $552,000 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-05.revenue_estimated | Revenue · estimate — report date 2025-11-05 | $599,330 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-05.eps_actual | EPS · reported — report date 2025-11-05 | −$0.1700 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-05.eps_estimated | EPS · estimate — report date 2025-11-05 | −$0.1200 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed | |
fin.cash_investments | Cash and short-term investments | $111.74M | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. | |
fin.opcf_latest | Latest-quarter operating cash flow | −$18.44M | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Period end: 2026-06-30. Negative operating cash flow means cash used. This figure is not a cash-runway estimate. | |
fin.long_term_investments | Long-term investments (classification unverified) | $60.32M | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.total_debt | Total debt | $3.25M | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.price_to_book | Price to book value | 1.87× | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
fin.opcf.depth.2026-06-30.operating_cash_flow_m | Operating cash flow — period end 2026-06-30 | −$18.44M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-03-31.operating_cash_flow_m | Operating cash flow — period end 2026-03-31 | −$25.64M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-06-30.capex_m | Capital expenditure (reported) — period end 2026-06-30 | −$80,000 | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-03-31.capex_m | Capital expenditure (reported) — period end 2026-03-31 | −$280,000 | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-12-31.operating_cash_flow_m | Operating cash flow — period end 2025-12-31 | −$16.35M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-12-31.capex_m | Capital expenditure (reported) — period end 2025-12-31 | $20,000 | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-09-30.operating_cash_flow_m | Operating cash flow — period end 2025-09-30 | −$32.02M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-09-30.capex_m | Capital expenditure (reported) — period end 2025-09-30 | −$900,000 | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
earn.pt_range | Analyst price target, low to high | $1.90 – $1.90 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
earn.pt_consensus | Consensus analyst price target | $1.90 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
earn.pt_median | Median analyst price target | $1.90 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
own.insiders | Insider transactions via FMP | 15 transactions · 0 purchases, 14 sales, 1 other transactions · 5 identified insiders · of the newest 15 records, those within the last 180 days, newest dated Sep 22, 2026 | FMP | Financial Modeling Prep (FMP), carrying Form 4 transaction records — Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent. | |
own.institutions.depth.ownership_pct | Institutional ownership | 24.3% | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.ownership_pct_previous_quarter | Previous quarter · ownership | 29.2% | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.institutions.depth.holders | Reporting holders | 148 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.holders_previous_quarter | Previous quarter · holders | 164 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.top_holders.depth.holder_0.shares | Vanguard Capital Management LLC — shares in provider snapshot | 7,578,208 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_1.shares | Ark Investment Management LLC — shares in provider snapshot | 7,167,738 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_2.shares | Blackrock, INC. — shares in provider snapshot | 5,225,352 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_3.shares | Nikko Asset Management Americas, INC. — shares in provider snapshot | 3,885,230 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_4.shares | Sumitomo Mitsui Trust Group, INC. — shares in provider snapshot | 3,885,230 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. |
UNRECORDED — 4 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.history | Reported versus estimated, recent quarters | EPS beat 5 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-10-05 | |
fin.scores | Distress and quality screens | Altman Z 7.42 · Piotroski F 2 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-04 · Expired observation | |
px.range52 | 52-week range | $0.69 – $3.10 | UNRECORDED | Stored company-profile observation — Captured 2026-10-05 | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROE -47.3% · ROA -48.7% · current ratio 12.60 · earnings yield -58.0% · free-cash-flow yield -58.5% | — | UNRECORDED | Stored key metrics — Date unknown |
COMPUTED — 3 facts from our arithmetic, formula restated
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
fin.mcap_to_cash | Market value per dollar of cash and short-term investments | 2.26× | — | COMPUTED | Computed on this page from the figures above — The market capitalisation printed on this page divided by cash and short-term investments of $111.74M at Jun 30, 2026. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. Market cap record date: 2026-10-05. Balance-sheet reference date: 2026-06-30. The inputs do not establish a single common source date for this ratio. |
earn.history.depth.2026-08-13.revenue_actual.comparison | Latest report · revenue vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported revenue ($344,000) with the recorded estimate ($302,000) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
earn.history.depth.2026-08-13.eps_actual.comparison | Latest report · EPS vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported EPS (−$0.1100) with the recorded estimate (−$0.1133) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
OURS — 2 facts from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
ours.moonshot | MoonshotScore v2 | 26 of 100 · Weak · pillars 16 / 56 / 25 / 38 / 79 | OURS | Stock Expert AI MoonshotScore v2 engine | |
ours.moonshot_change | MoonshotScore movement | 26 (stored snapshot Oct 5, 2026) → 26 (current publication computed Oct 6, 2026) (0) | OURS | Stock Expert AI current score publication and immutable score snapshots — The current score publication is not yet represented in the immutable snapshot archive. |
Fact-family notes
- Quarterly statement note. Source series as of 2026-06-30. USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow. Applies to Fact IDs:
fin.q_table.depth.2026-06-30.revenue_k,fin.q_table.depth.2026-06-30.rd_k,fin.q_table.depth.2026-06-30.sga_k,fin.q_table.depth.2026-06-30.operating_result_k,fin.q_table.depth.2026-03-31.revenue_k,fin.q_table.depth.2026-03-31.rd_k,fin.q_table.depth.2026-03-31.sga_k,fin.q_table.depth.2026-03-31.operating_result_k,fin.q_table.depth.2025-12-31.revenue_k,fin.q_table.depth.2025-12-31.rd_k,fin.q_table.depth.2025-12-31.sga_k,fin.q_table.depth.2025-12-31.operating_result_k,fin.q_table.depth.2025-09-30.revenue_k,fin.q_table.depth.2025-09-30.rd_k,fin.q_table.depth.2025-09-30.sga_k,fin.q_table.depth.2025-09-30.operating_result_k. - Earnings-history note. Source series as of 2026-08-13. Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined. Applies to Fact IDs:
earn.history.depth.2026-08-13.revenue_actual,earn.history.depth.2026-08-13.revenue_estimated,earn.history.depth.2026-08-13.revenue_actual.comparison,earn.history.depth.2026-08-13.eps_actual.comparison,earn.history.depth.2026-08-13.eps_actual,earn.history.depth.2026-08-13.eps_estimated,earn.history.depth.2026-05-07.revenue_actual,earn.history.depth.2026-05-07.revenue_estimated,earn.history.depth.2026-05-07.eps_actual,earn.history.depth.2026-05-07.eps_estimated,earn.history.depth.2026-03-03.revenue_actual,earn.history.depth.2026-03-03.revenue_estimated,earn.history.depth.2026-03-03.eps_actual,earn.history.depth.2026-03-03.eps_estimated,earn.history.depth.2025-11-05.revenue_actual,earn.history.depth.2025-11-05.revenue_estimated,earn.history.depth.2025-11-05.eps_actual,earn.history.depth.2025-11-05.eps_estimated. - Cash-flow note. Source series as of 2026-06-30. USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway. Applies to Fact IDs:
fin.opcf.depth.2026-06-30.operating_cash_flow_m,fin.opcf.depth.2026-03-31.operating_cash_flow_m,fin.opcf.depth.2026-06-30.capex_m,fin.opcf.depth.2026-03-31.capex_m,fin.opcf.depth.2025-12-31.operating_cash_flow_m,fin.opcf.depth.2025-12-31.capex_m,fin.opcf.depth.2025-09-30.operating_cash_flow_m,fin.opcf.depth.2025-09-30.capex_m.
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources used for research written 2026-09-13
Historical evidence preserved with this analysis. Current figures are listed separately above.
| Evidence | Captured value | Source date | Source type | Source |
|---|---|---|---|---|
| Business description | Quantum-Si incorporated operates within the life sciences sector, focusing on the creation of an advanced platform for individual molecule detection. This innovative technology is designed to streamline sample preparation and subsequent sequencing processes. The company offers a unique, proprietary single molecule detection system that draws on advancements from the semiconductor industry. This system is specifically applied to the field of proteomics, paving the way for next-generation protein sequencing. Established in 2013, Quantum-Si's headquarters are located in Guilford, Connecticut. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) company profile |
| Revenue by segment | Product: $2.29M; Service: $150,000 | 2025-12-31 | FMP | Financial Modeling Prep (FMP) revenue segmentation, from the company's 10-K |
| Quarterly income statement (USD thousands) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements |
| Annual revenue and net result (USD millions) | Captured record · 5 entries
| 2025-12-31 | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements |
| Management outlook — dated call excerpts | Captured record · 2 entries
Selected verbatim statements from the latest available call, dated by the transcript provider. Management expectations, not completed milestones or guarantees. Relative dates retain the speaker's wording. | 2026-08-12 | OFFICIAL | Company earnings call, transcript via Financial Modeling Prep (FMP) |
| Sector / industry (provider taxonomy) | Healthcare / Medical - Devices The company's SEC filings classify it under SIC 3829 — Measuring & Controlling Devices, NEC. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) company profile |
| Operating cash flow by quarter (USD millions) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements |
| Reported versus estimated, last 8 quarters | Captured record · 8 entries
| 2026-08-13 | FMP | Financial Modeling Prep (FMP) earnings |
| Cash, investments and debt | Total debt: $3.25M; Liquidity basis: cash and short-term investments; Total liabilities: $13.37M; Cash and short-term investments: $111.74M; Cash and investments: $172.10M; Long-term investments: $60.32M; Long-term investments classification: unclassified Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's balance sheet |
| Cash and investment components | Total basis: cash short and long-term investments; Total: $172.10M; Cash and short-term investments: $111.70M; Long-term investments: $60.30M; Long-term investments classification: unclassified Sums the balance sheet's cash and short-term investments with its long-term investments.; The long-term investment field does not establish marketability; the sum is not a measure of available liquidity.; These provider fields do not establish investment access restrictions or explain differences from third-party cash figures. | 2026-06-30 | COMPUTED | Computed from the balance sheet |
| Cash and short-term investments over time (USD millions) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's quarterly balance sheets |
| Cash decline over the reported window | To: 2026-06-30; From: 2024-09-30; Periods: 7; Cash basis: cash and short-term investments; Closing balance: $111.70M; Decline: $84.60M; Opening balance: $196.30M; Average change per period: $12.10M Change in cash, cash equivalents and short-term investments between the 2024-09-30 and 2026-06-30 balance sheets.; This is a balance change, not operating burn: financing and investing move it too.; Averaged over 7 reporting periods of unequal length. | 2026-06-30 | COMPUTED | Computed from reported balances |
| Distress and quality screens | Altman Z-score: 0.25; Piotroski F-score: 2 Altman Z below 1.8 is the conventional distress zone. The screen is built for manufacturers and industrials; for banks, insurers and property companies it is not a meaningful reading. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) financial scores |
| Listing-status notice (8-K Item 3.01) | Form: 8-K; Item: 3.01; Filed: 2026-07-24; Event date: 2026-07-23; Item description: Notice of delisting or failure to satisfy a continued listing rule or standard; transfer of listing Item 3.01 covers a delisting or continued-listing notice AND a voluntary transfer between exchanges; which one this is, and any cure period or deadline, are stated inside the filing. Read the linked document rather than inferring either from the filing date. | 2026-07-24 | OFFICIAL | SEC EDGAR — Form 8-K, Item 3.01 |
| Next earnings report | Date: 2026-11-04; EPS estimate: -$0.13 per share; Revenue estimate: $280,000 The date is our provider's estimate until the company confirms it. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) earnings calendar |
| Analyst revenue and earnings estimates (average) | Captured record · 4 entries
At most 3 analysts contributed — treat this as thin coverage, not a consensus. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) analyst estimates |
| Most recent periodic reports | 2026-08-13 | OFFICIAL | SEC EDGAR filer submissions | |
| Cash against market value | As of: 2026-06-30; Cash basis: cash and short-term investments; Net cash: $108.50M; Total debt: $3.30M; Cash and investments: $111.70M Price-based multiples captured at research time are not repeated here; the page shows each once, from current figures with their own dates. Cash is the latest reported cash and short-term investment balance; long-term investments are excluded. Market capitalization is the latest provider value.; The reported balance does not establish unrestricted availability or liquidation value.; The two are measured on different dates — the balance sheet is a quarter-end, the market cap is a recent close.; Debt is total debt as reported, including operating lease liabilities where the filer includes them. | 2026-06-30 | COMPUTED | Computed from the balance sheet and the latest market capitalization |
| Recent SEC filings |
| 2026-08-13 | OFFICIAL | SEC EDGAR filer submissions |
Data provided for informational purposes only.